MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung Cancer

被引：26

作者：

Camidge, D. Ross ^{[1
]}

Davies, Kurtis D. ^{[1
]}

机构：

[1] Univ Colorado, Anschutz Med Campus, Aurora, CO USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 11期

关键词：

AMPLIFICATION; SELECTION; NSCLC;

D O I：

10.1200/JCO.19.00033

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：855 / +

页数：4

共 17 条

[1] TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI [J].

Ahn, M. ;

Han, J. ;

Sequist, L. ;

Cho, B. C. ;

Lee, J. S. ;

Kim, S. ;

Su, W. ;

Tsai, C. ;

Yang, J. C. ;

Yu, H. ;

Horn, L. ;

Lee, K. ;

Haddad, V. ;

Frigault, M. ;

Ahmed, G. ;

Yang, L. ;

Ghiorghiu, D. ;

Oxnard, G. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S1768-S1768

[2]

[Anonymous], J CLIN ONCOL S

[3] A phase 1b trial of RORγ agonist LYC-55716 in combination with pembrolizumab to evaluate safety, efficacy, and immune biomarker profiles in patients with metastatic non-small cell lung cancer [J].

Camidge, D. Ross ;

Gadgeel, Shirish M. ;

Weems, Garry Alan ;

Wilkins, H. Jeffrey ;

Johnson, Melissa Lynne .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[4] A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY plus E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx plus ) metastatic NSCLC. [J].

Camidge, D. Ross ;

Moran, Teresa ;

Demedts, Inge ;

Grosch, Heidrun ;

Di Mercurio, Jean-Pierre ;

Mileham, Kathryn Finch ;

Molina, Julian R. ;

Vidal, Oscar Juan ;

Bepler, Gerold ;

Goldman, Jonathan Wade ;

Lewanski, Conrad ;

Park, Keunchil ;

Wallin, Johan ;

Wijayawardana, Sameera R. ;

Wang, Xuejing Aimee ;

Wacheck, Volker ;

Smit, Egbert F. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[5] Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC) [J].

Camidge, D. Ross ;

Ou, Sai-Hong Ignatius ;

Shapiro, Geoffrey ;

Otterson, Gregory Alan ;

Villaruz, Liza Cosca ;

Villalona-Calero, Miguel Angel ;

Iafrate, A. John ;

Varella-Garcia, Marileila ;

Dacic, Sanja ;

Cardarella, Stephanie ;

Zhao, Weiqiang ;

Tye, Lesley ;

Stephenson, Patricia ;

Wilner, Keith D. ;

James, Leonard Philip ;

Socinski, Mark A. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[6] Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer [J].

Drilon, A. ;

Clark, J. ;

Weiss, J. ;

Ou, S. ;

Camidge, D. R. ;

Solomon, B. ;

Otterson, G. ;

Villaruz, L. ;

Riely, G. ;

Heist, R. ;

Shapiro, G. ;

Murphy, D. ;

Wang, S. ;

Usari, T. ;

Li, S. ;

Wilner, K. ;

Paik, P. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S348-S348

[7] Targeting MET in Lung Cancer: Will Expectations Finally Be MET? [J].

Drilon, Alexander ;

Cappuzzo, Federico ;

Ignatius, Sai-Hong ;

Camidge, D. Ross .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :15-26

[8] Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer [J].

Lai, Gillianne Gy ;

Lim, Tse Hui ;

Lim, John ;

Liew, Perry J. R. ;

Kwang, Xue Lin ;

Nahar, Rahul ;

Aung, Zaw Win ;

Takano, Angela ;

Lee, Yin Yeng ;

Lau, Dawn P. X. ;

San Tan, Gek ;

Tan, Sze Huey ;

Tan, Wan Ling ;

Ang, Mei-Kim ;

Toh, Chee Keong ;

Tan, Bien Soo ;

Devanand, Anantham ;

Too, Chow Wei ;

Gogna, Apoorva ;

Ong, Boon Hean ;

Koh, Tina P. T. ;

Kanesvaran, Ravindran ;

Ng, Quan Sing ;

Jain, Amit ;

Rajasekaran, Tanujaa ;

Yuan, Ju ;

Lim, Tony Kiat Hon ;

Lim, Alvin S. T. ;

Hillmer, Axel M. ;

Lim, Wan Teck ;

Iyer, N. Gopalakrishna ;

Tam, Wai Leong ;

Zhai, Weiwei ;

Tan, Eng-Huat ;

Tan, Daniel S. W. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (11) :876-+

[9] Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis [J].

Noonan, Sinead A. ;

Berry, Lynne ;

Lu, Xian ;

Gao, Dexiang ;

Baron, Anna E. ;

Chesnut, Patrick ;

Sheren, Jamie ;

Aisner, Dara L. ;

Merrick, Dan ;

Doebele, Robert C. ;

Varella-Garcia, Marileila ;

Camidge, D. Ross .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (08) :1293-1304

[10] Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion [J].

Piotrowska, Zofia ;

Isozaki, Hideko ;

Lennerz, Jochen K. ;

Gainor, Justin F. ;

Lennes, Inga T. ;

Zhu, Viola W. ;

Marcoux, Nicolas ;

Banwait, Mandeep K. ;

Digumarthy, Subba R. ;

Su, Wenjia ;

Yoda, Satoshi ;

Riley, Amanda K. ;

Nangia, Varuna ;

Lin, Jessica J. ;

Nagy, Rebecca J. ;

Lanman, Richard B. ;

Dias-Santagata, Dora ;

Mino-Kenudson, Mari ;

Iafrate, A. John ;

Heist, Rebecca S. ;

Shaw, Alice T. ;

Evans, Erica K. ;

Clifford, Corinne ;

Ou, Sai-Hong, I ;

Wolf, Beni ;

Hata, Aaron N. ;

Sequist, Lecia, V .

CANCER DISCOVERY, 2018, 8 (12) :1529-1539

← 1 2 →